UK-101

• Description :

  UK-101 is a potent and selective immunoproteasome β1i (LMP2) inhibitor with an IC50 value of 104 nM, displays 144- and 10-fold selectivity over β1c (IC50=15 μM) and β5 subunit (IC50=1 μM), respectivey[1]. UK-101 induces cell apoptosis and can be used for the study of prostate cancer[2].

• UNSPSC :

  12352005

• Target :

  Apoptosis; Proteasome

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Metabolic Enzyme/Protease

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/uk-101.html

• Purity :

  99.58

• Solubility :

  DMSO : 7.3 mg/mL (ultrasonic; warming)

• Smiles :

  O=C([C@]1(CO1)CO[Si](C)(C)C(C)(C)C)[C@H](CC(C)C)NC([C@H](C)NC(CCCCCC)=O)=O

• Molecular Formula :

  C25H48N2O5Si

• Molecular Weight :

  484.74

• References & Citations :

  [1]de Bruin G, et al. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes. J Med Chem. 2014 Jul 24;57 (14) :6197-209.|[2]Wehenkel M, et al. A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer. 2012 Jun 26;107 (1) :53-62.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1000313-40-5]